K-CONNECT
PLATFORM

UPCOMING EVENT
D
H
M
S
K-CONNECT APAC 2025
Logo - The K-CONNECT Platform
Experts Meeting

Empowering the Potential of ctDNA-MRD

An academic event in Danang, Vietnam, to foster collaboration and knowledge sharing among oncologists in the Asia-Pacific region.
Days
Hours
Minutes
Seconds
FOR MORE DETAILS

EXPERTS MEETING

| K-CONNECT APAC 2025

  • Da Nang, Vietnam

An exclusive event in Danang, Vietnam, bringing together leading oncologists and researchers from across the AsiaPacific region. K-CONNECT APAC 2025 aims to delve into the cutting-edge applications of ctDNA-MRD, share realworld experiences, and collaborate on pioneering advancements in precision oncology. 

The event will feature over 60 invited oncologists as speakers and delegates, hosted by Gene Solutions.

For more details

CLINICAL TRIAL SUPPORT

| A COLLABORATIVE EFFORT TO ADVANCE CANCER CARE

The K-CONNECT Platform, in collaboration with local partners and Biopharma companies, offers oncologist access to a complimentary first K-TRACK test, or Applicants for supported diagnostics assays in clinical research. This initiative underscores our commitment to advancing precision oncology and improving patient outcomes.​​
Discuss collaboration​

EXPERIENCE MRD

| LEADING THE FUTURE OF PRECISION ONCOLOGY

Join leading oncologists across Asia in transforming cancer care through cutting-edge ctDNA-MRD technology. ​

Oncologists can easily access this offer through the K-CONNECT Platform. Simply log in to your account and follow the designated pathway. Our user-friendly interface will guide you through the process, ensuring a seamless experience.​
Explore trial program opportunities​

WEBINARS

A series of webinars for knowledge sharing, covering the latest advancements in cancer treatment and emerging technologies in precision medicine.
2025
July 09
1st Webinar
Value of CGTP & ctDNA monitoring for advanced stage cancers
September
2nd Webinar
Coming soon
November
3rd Webinar
Coming soon
Sign up now
Online Resources

CASE STUDIES

When Molecular Signals Speak First: How ctDNA Monitoring Revealed Lung Cancer Recurrence Before Imaging

Source:

Patient ZMB501 | JCO Oncology Advances

Cancer type:

Lung Cancer

The story of Rajesh, a 75-year-old man diagnosed with stage IA lung adenocarcinoma, reminds us that while CT scans remain a staple in surveillance, molecular recurrence can emerge well before structural changes are visible.
kconnect.genesolutions.com when molecular signals speak first how ctdna monitoring revealed lung cancer recurrence before imaging 9 1 - The K-CONNECT Platform
Rajesh A 75-year-old man
Find out
kconnect.genesolutions.com when molecular signals speak first how ctdna monitoring revealed lung cancer recurrence before imaging slide3 - The K-CONNECT Platform

Personalizing Colon Cancer Management: How Genomic Profiling and ctDNA Monitoring Informed Adjuvant Therapy in a Stage III Case

Source:

Patient ZMC502 | JCO Oncology Advances

Cancer type:

Colorectal Cancer

This real-world case of Long, a 46-year-old man diagnosed with stage III sigmoid colon cancer, illustrates how both approaches informed risk stratification and a tailored adjuvant treatment strategy.
kconnect.genesolutions.com personalizing colon cancer management how genomic profiling and ctdna monitoring informed adjuvant therapy in a stage iii case 50s asian man 1 - The K-CONNECT Platform
Long A 46-year-old man
Find out
kconnect.genesolutions.com personalizing colon cancer management how genomic profiling and ctdna monitoring informed adjuvant therapy in a stage iii case slide2 - The K-CONNECT Platform

Integrating Genomic Profiling and ctDNA Monitoring to Guide HER2+ Breast Cancer Therapy

Source:

Patient ZMB501 | JCO Oncology Advances

Cancer type:

Breast Cancer

Meet Maya, a 35-year-old woman diagnosed with HER2-positive breast cancer. Her story highlights the real-world impact of using both technologies to personalize treatment, track progress, and achieve long-term disease control.
kconnect.genesolutions.com integrating genomic profiling and ctdna monitoring to guide her2 breast cancer therapy 1 1 - The K-CONNECT Platform
Maya A 35-year-old woman
Find out
kconnect.genesolutions.com integrating genomic profiling and ctdna monitoring to guide her2 breast cancer therapy slide1 - The K-CONNECT Platform

PUBLICATIONS

ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer​

Publisher:

clinicaltrials.gov

Publication date:

September 16, 2023

Key finding:

This is a prospective observational study, in collaboration with 3 hospitals (175 Military Hospital, Nguyen Tri Phuong Hospital, and 108 Military Central Hospital), plans to recruit 100 patients with stage II-III rectal cancer and indicated for total neoadjuvant therapy. K-TRACK assay will use to evaluate value of ctDNA in Predict the Efficacy of TNT for Rectal Cancer​.

Read more​

Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer

Publisher:

clinicaltrials.gov

Publication date:

October 18, 2023

Key finding:

This prospective and observational study, in collaboration with University Medical Center HCMC, plans to recruit 75 patients with stage II-III HER+/Triple Negative Breast cancer and indicated for neoadjuvant chemotherapy. K-TRACK assay will use aim to determine the detection rate and change of ctDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.

Read more​

SPEAKERS & PANELISTS

au - The K-CONNECT Platform
kconnect.genesolutions.com nick pavlakis kol nickpavlakis 512 photo picsart aiimageenhancer - The K-CONNECT Platform

Professor

Nick Pavlakis

University of Sydney, Australia
id - The K-CONNECT Platform
Sita Laksmi Andarini

Associate Professor

Sita Laksmi Andarini

National Referral for Repiratory diseases, RSUP Persahabatan
id - The K-CONNECT Platform
kconnect.genesolutions.com sita laksmi andarini kol samuelmrccc 512 photo - The K-CONNECT Platform

Doctor

Samuel Haryono

Siloam MRCCC, Jakarta, Indonesia
vn - The K-CONNECT Platform
Mai Trong Khoa

Professor

Mai Trong Khoa

Vice President, Vietnam Immunotherapies Association
vn - The K-CONNECT Platform
Le Thuong Vu

Associate Professor

Le Thuong Vu

University Medical Center, Ho Chi Minh City
vn - The K-CONNECT Platform
Nguyen Thi Minh Phuong

Associate Professor

Nguyen Thi Minh Phuong

Hong Ngoc Hospital - Phuc Truong Minh
th - The K-CONNECT Platform
Rattiya Cheewakriangkrai

Doctor

Rattiya Cheewakriangkrai

Chiangmai Ram Hospital, Thailand
th - The K-CONNECT Platform
Sutima Luangdilok, PhD, MD

Associate Professor

Sutima Luangdilok

Chulalongkorn University, Thailand
th - The K-CONNECT Platform
Pornchai O-Charoenrat 

Professor

Pornchai O-Charoenrat 

Chaophya Hospital, Thailand
ph - The K-CONNECT Platform
Maria Belle Francia

Doctor

Maria Belle Francia

St. Lukes BGC
hk - The K-CONNECT Platform
Au Siu Kie

Doctor

Au Siu Kie

President of Hong Kong Precision Oncology Society, Hong Kong
hk - The K-CONNECT Platform
Aya El Helali

Professor

Aya El Helali

Center of Cancer Medicine, The University of Hong Kong
hk - The K-CONNECT Platform
kconnect.genesolutions.com feng mingspringkong kol kongfengming 512 photo - The K-CONNECT Platform

Professor

Feng-Ming (Spring) Kong

The University of Hong Kong
vn - The K-CONNECT Platform
Nguyen Duy Sinh

Medical Lead (Oncology division)

Nguyen Duy Sinh

Gene Solutions
vn - The K-CONNECT Platform
Tu Ngoc Ly Lan

Principal Investigator

Tu Ngoc Ly Lan

Gene Solutions

Contact Us

© 2025 GENE SOLUTIONS. All rights reserved.
Facebook Youtube Linkedin

The K-CONNECT Platform creates as a collaborative initiative that brings together leading oncologists and researchers from across the region. The platform serves as a bridge between cutting-edge technology and expert practitioners, aiming to unlock the potential of ctDNA-MRD for precision and personalized oncology.​

K-CONNECT APAC 2025